QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device ...

 profound-medical-q2-eps-052-misses-035-estimate-sales-2211m-miss-3533m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(...

Core News & Articles

Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device ...

 profound-medical-q1-eps-036-misses-028-estimate-sales-262m-miss-350m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(...

Core News & Articles

– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer –– TULSA had no blood l...

 lake-street-maintains-buy-on-profound-medical-lowers-price-target-to-11

Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target from $17...

 profound-medical-q4-eps-020-beats-033-estimate-sales-418m-miss-427m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0....

Core News & Articles

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON ED...

 profound-medical-q3-2024-gaap-eps-038-misses-030-estimate-sales-2832m-miss-3006m-estimate

Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(...

 profound-medical-affirms-fy2024-sales-guidance-to-1100m-1200m--vs-est-1123m

Profound Medical (NASDAQ:PROF) affirms FY2024 sales outlook from $11.00 million-12.00 million to $11.00 million-12.00 million.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION